In pediatric oncology, DNMT inhibitors are used to treat specific types of cancers, such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). These drugs work by reactivating tumor suppressor genes that have been silenced by abnormal DNA methylation patterns. Additionally, some research suggests that DNMT inhibitors may have potential therapeutic applications in treating certain genetic disorders characterized by aberrant methylation.
